Free Trial

Veru (VERU) Competitors

-0.03 (-2.11%)
(As of 05/21/2024 ET)


Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Xeris Biopharma (XERS), Nature's Sunshine Products (NATR), Werewolf Therapeutics (HOWL), Merrimack Pharmaceuticals (MACK), Conduit Pharmaceuticals (CDT), Trevi Therapeutics (TRVI), Eliem Therapeutics (ELYM), Ovid Therapeutics (OVID), Zevra Therapeutics (ZVRA), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.

Veru vs.

Xeris Biopharma (NASDAQ:XERS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Veru had 17 more articles in the media than Xeris Biopharma. MarketBeat recorded 17 mentions for Veru and 0 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.55 beat Veru's score of 0.00 indicating that Veru is being referred to more favorably in the news media.

Company Overall Sentiment
Xeris Biopharma Neutral
Veru Positive

Xeris Biopharma currently has a consensus target price of $4.63, suggesting a potential upside of 131.25%. Veru has a consensus target price of $4.00, suggesting a potential upside of 187.77%. Given Xeris Biopharma's higher possible upside, analysts plainly believe Veru is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)

Xeris Biopharma has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Veru has a beta of -0.47, meaning that its share price is 147% less volatile than the S&P 500.

Xeris Biopharma has a net margin of -37.58% compared to Xeris Biopharma's net margin of -265.27%. Xeris Biopharma's return on equity of -130.13% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-37.58% -16,662.63% -19.58%
Veru -265.27%-130.13%-67.82%

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Xeris Biopharma has higher revenue and earnings than Veru. Xeris Biopharma is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$163.91M1.81-$62.26M-$0.47-4.26

Veru received 130 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 69.59% of users gave Veru an outperform vote.

Xeris BiopharmaOutperform Votes
Underperform Votes
VeruOutperform Votes
Underperform Votes


Veru beats Xeris Biopharma on 10 of the 17 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERU vs. The Competition

MetricVeruPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$203.47M$6.97B$5.06B$8.00B
Dividend YieldN/A2.75%43.25%3.91%
P/E Ratio-4.0922.64154.3118.58
Price / Sales12.48273.802,489.8284.71
Price / CashN/A20.5833.3629.27
Price / Book6.325.395.034.46
Net Income-$93.15M$148.43M$104.04M$213.22M
7 Day Performance-5.44%0.70%0.15%0.85%
1 Month Performance6.11%5.16%4.81%6.20%
1 Year Performance21.93%-5.00%7.52%10.03%

Veru Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Xeris Biopharma
3.5276 of 5 stars
Nature's Sunshine Products
3.6848 of 5 stars
+45.5%$294.25M$445.32M18.48814Positive News
Werewolf Therapeutics
1.6722 of 5 stars
Merrimack Pharmaceuticals
0 of 5 stars
N/AN/A$219.69MN/A-189.00426Earnings Report
Dividend Increase
Analyst Upgrade
High Trading Volume
Conduit Pharmaceuticals
0 of 5 stars
N/AN/A$209.68MN/A0.007Positive News
Trevi Therapeutics
2.7246 of 5 stars
Eliem Therapeutics
0 of 5 stars
N/A+170.3%$227.03MN/A-5.579Positive News
Ovid Therapeutics
4.2024 of 5 stars
-9.9%$228.72M$391,695.00-4.3140Analyst Revision
Zevra Therapeutics
0.6078 of 5 stars
Generation Bio
2.3271 of 5 stars
-20.0%$235.38M$5.90M-1.81174Gap Up

Related Companies and Tools

This page (NASDAQ:VERU) was last updated on 5/22/2024 by Staff

From Our Partners